Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.42 |
| ▸ | CASP3 | P42574 | 3/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22925729 | 0.86 | CHEK1 (0.44) | CHEK1CASP3CHEK2AKT1 | |
| SCHEMBL22925955 | 0.84 | CASP3 (0.42) | CHEK1CASP3KCNH2GRM5HDAC4 | |
| SCHEMBL22925610 | 0.83 | CASP3 (0.43) | CHEK1CASP3CHEK2KCNH2GRM5 | |
| SCHEMBL22925966 | 0.79 | CHEK1 (0.41) | CHEK1CHEK2AKT1KCNH2 | |
| SCHEMBL28733658 | 0.76 | CASP3 (0.41) | CASP3 | |
| SCHEMBL29620885 | 0.76 | CASP3 (0.39) | CASP3 | |
| SCHEMBL28733662 | 0.76 | CASP3 (0.39) | CASP3 | |
| SCHEMBL22925810 | 0.76 | CASP3 (0.39) | CASP3 | |
| SCHEMBL22925914 | 0.74 | S1PR1 (0.42) | CHEK1CASP3HDAC4HDAC6 | |
| SCHEMBL28939269 | 0.72 | CHEK1 (0.42) | CHEK1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| EP-4003986-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-06-01 | — | — | EP | disclosed |
| CN-114450281-A | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2022-05-06 | — | — | CN | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | CHEK1 1509/4885CASP3 1714/4885CHEK2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.